Cancer: Delcath lands expanded CE Mark for organ-isolating chemo treatment

October 23, 2012 by MassDevice staff

Delcath lands expanded CE Mark approval in the European Union to market its targeted chemotherapy delivery system with a drug commonly used to destroy liver tumors.

Delcath logo

Delcath Systems (NSDQ:DCTH) won expanded CE Mark approval in the European Union for its ChemoSat organ-isolating cancer treatment system, landing indication for a new drug used to target liver tumors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp